Terms: = Kidney tumors AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027
13 results:
1. The GATOR2 complex maintains lysosomal-autophagic function by inhibiting the protein degradation of MiT/TFEs.
Yang S; Ting CY; Lilly MA
Mol Cell; 2024 Feb; 84(4):727-743.e8. PubMed ID: 38325378
[TBL] [Abstract] [Full Text] [Related]
2. One step at a time: Melanocytic differentiation in fusion-driven cutaneous neoplasms.
Linos K
J Cutan Pathol; 2023 Dec; 50(12):1116-1118. PubMed ID: 37844955
[TBL] [Abstract] [Full Text] [Related]
3. Phase 1 study of mtorc1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Voss MH; Gordon MS; Mita M; Rini B; Makker V; Macarulla T; Smith DC; Cervantes A; Puzanov I; Pili R; Wang D; Jalal S; Pant S; Patel MR; Neuwirth RL; Enke A; Shou Y; Sedarati F; Faller DV; Burris HA
Br J Cancer; 2020 Nov; 123(11):1590-1598. PubMed ID: 32913286
[TBL] [Abstract] [Full Text] [Related]
4. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract] [Full Text] [Related]
5. New agents and new targets for renal cell carcinoma.
Philips GK; Atkins MB
Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract] [Full Text] [Related]
7. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract] [Full Text] [Related]
8. microRNA-21 governs torc1 activation in renal cancer cell proliferation and invasion.
Dey N; Das F; Ghosh-Choudhury N; Mandal CC; Parekh DJ; Block K; Kasinath BS; Abboud HE; Choudhury GG
PLoS One; 2012; 7(6):e37366. PubMed ID: 22685542
[TBL] [Abstract] [Full Text] [Related]
9. Therapy for non-clear cell histologies in renal cancer.
Bitting RL; Madden J; Armstrong AJ
Curr Clin Pharmacol; 2011 Aug; 6(3):169-80. PubMed ID: 21861801
[TBL] [Abstract] [Full Text] [Related]
10. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
[TBL] [Abstract] [Full Text] [Related]
11. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract] [Full Text] [Related]
12. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.
Hartman TR; Nicolas E; Klein-Szanto A; Al-Saleem T; Cash TP; Simon MC; Henske EP
Oncogene; 2009 Apr; 28(13):1594-604. PubMed ID: 19234517
[TBL] [Abstract] [Full Text] [Related]
13. Recurrent fusion oncogenes in carcinomas.
Teixeira MR
Crit Rev Oncog; 2006 Dec; 12(3-4):257-71. PubMed ID: 17425505
[TBL] [Abstract] [Full Text] [Related]
